Pancreatic Cancer Research

ResearcherShanghai UniversityActive in the last 2 years

Yusheng Ye

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5627-1593; OpenAlex author ID A5101712020. Sources: OpenAlex.

Their work

Papers
12 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
10
Papers, trials and grants by year

2020: 1 paper · 2021: 4 papers · 2022: 3 papers · 2023: 1 paper · 2024: 2 papers · 2025: 1 paper

Papers 12

  1. ADJUPANC protocol: a phase III study of adjuvant chemotherapy versus chemoradiotherapy for pancreatic cancer. Co-author DOI 10.1080/14796694.2025.2522061↗
  2. Immune profiling of pancreatic cancer for radiotherapy with immunotherapy and targeted therapy: Biomarker analysis of a randomized phase 2 trial. Co-author DOI 10.1016/j.radonc.2023.109941↗
  3. Stereotactic body radiation therapy for the primary tumor and oligometastases versus the primary tumor alone in patients with metastatic pancreatic cancer. First author DOI 10.1186/s13014-024-02493-8↗
  4. Effect of stereotactic body radiotherapy dose escalation plus pembrolizumab and trametinib versus stereotactic body radiotherapy dose escalation plus gemcitabi… Co-author DOI 10.1016/j.eclinm.2022.101764↗
  5. Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer… Co-author DOI 10.1016/s1470-2045(22)00066-3↗
  6. Biologically effective doses of 60-70Gy versus >70Gy of stereotactic body radiotherapy (SBRT) combined with chemotherapy in locally advanced pancreatic cancer:… Co-author DOI 10.1136/bmjopen-2021-049382↗
  7. Uniform expansion vs. non-uniform expansion of gross tumor volume based on recurrence patterns to form planning target volume of stereotactic body radiation th… Co-author DOI 10.21203/rs.3.rs-1919548/v1↗
  8. Stereotactic body radiation therapy with sequential S-1 for patients with locally advanced pancreatic cancer and poor performance status: An open-label, single… Co-author DOI 10.1016/j.radonc.2021.07.009↗
  9. Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer… Co-author DOI 10.1016/s1470-2045(21)00286-2↗
  10. Personalized designs of adjuvant radiotherapy for pancreatic cancer based on molecular profiles. Co-author DOI 10.1111/cas.14486↗
  11. Development and Validation of Multicenter Predictive Nomograms for Locally Advanced Pancreatic Cancer After Chemoradiotherapy. Co-author DOI 10.3389/fonc.2021.688576↗
  12. Failure patterns and outcomes of dose escalation of stereotactic body radiotherapy for locally advanced pancreatic cancer: a multicenter cohort study. Co-author DOI 10.1177/1758835920977155↗

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yangsen Cao · 12 shared papers, 2020–2025 · strength 2.06
  2. Lingong Jiang · 12 shared papers, 2020–2025 · strength 2.06
  3. Xiaofei Zhu · 12 shared papers, 2020–2025 · strength 2.06
  4. Huojun Zhang · 11 shared papers, 2020–2024 · strength 1.78
  5. Wenyu Liu · 7 shared papers, 2021–2025 · strength 1.34
  6. Shuiwang Qing · 3 shared papers, 2020–2021 · strength 0.35
  7. Gang Jin · 2 shared papers, 2021–2022 · strength 0.29
  8. Ting‐Shi Su · 2 shared papers, 2020–2021 · strength 0.23
  9. Yuxin Shen · 1 shared paper, 2021 · strength 0.13
  10. Xixu Zhu · 1 shared paper, 2021 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.